Video Series

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

A panelist discusses how health system leaders should focus resources on implementing multidisciplinary care teams, standardizing staging/severity assessments, and ensuring access to recommended treatments outlined in current hidradenitis suppurativa (HS) guidelines. Priority areas include early diagnosis through provider education, establishing clear referral pathways to specialists, comprehensive symptom management including pain control, and tracking patient outcomes against quality metrics to improve care delivery and reduce disease burden.

Panelists discuss how uncomplicated urinary tract infection (UTI) recurrence affects 20% to 30% of female patients within 6 months of initial infection, with contributing factors including anatomical variances, hormonal changes, genetic predisposition, insufficient treatment duration, resistant pathogens, and biofilm formation that persists despite proper adherence to standard antibiotic protocols.

Experts discuss how the role of oncology pharmacists in managing metastatic colorectal cancer (mCRC) has evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications, and explore the impact of this expanded role on patient outcomes and how pharmacists can leverage medication knowledge to optimize treatment and patient care further.

Experts discuss the typical patient journey for an individual with metastatic colorectal cancer (mCRC), highlighting where pharmacists participate in the process. They also explore how pharmacists collaborate with oncologists and other multidisciplinary team members to provide comprehensive care for patients with mCRC.

Panelists discuss how social determinants of health significantly influence uncomplicated urinary tract infection (UTI) prevalence and outcomes, with patients with lower income, those from rural areas, and those lacking consistent health care access experiencing higher infection rates, delayed treatment, increased complications, and poorer overall treatment success.

Panelists discuss how their practices have observed an increasing trend in uncomplicated urinary tract infections (UTIs), particularly among younger adult women and those with recurrent infections, noting potential contributing factors such as antibiotic resistance patterns and delayed care-seeking behaviors.

Panelists discuss how health care institutions have established structured care pathways for nonspecialist providers to evaluate mild cognitive impairment and mild dementia, incorporating validated questionnaires, standardized screening protocols, and clear referral guidelines to ensure consistent assessment across diverse clinical settings.

Panelists discuss how health care institutions employ comprehensive screening protocols for Alzheimer disease, including cognitive assessments, biomarker testing, and regular monitoring of at-risk populations, to facilitate early symptom identification and timely diagnosis that enables prompt intervention and improved patient outcomes.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular risk reduction in noninsulin-treated T2D.

Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.

Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access to updated treatment guidelines to address these issues while also expressing eagerness for future advancements in Bruton tyrosine kinase (BTK) inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.

A panelist discusses how guidelines are important for knowing when patient care starts, the progress of the patients care, and if the patient is satisfied with the response. Treatment guidelines are available for the 3 stages of hidradenitis suppurativa (HS): Hurley 1, Hurley 2, and Hurley 3. High scar scoring is also used to examine improvement in scarring over time. In real-world cases, guidelines have little to no impact on physicians treating HS, and most people often go to urgent care centers or primary care physicians when they are experiencing symptoms of HS. Health providers do not utilize guidelines except in clinical trials.

Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.

Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.

Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of patient education to improve adherence and ensure positive treatment outcomes.

Panelist discusses how health systems can improve communication and coordination among specialists through integrated care models and digital platforms. Centers of Excellence promote health equity by providing specialized care in underserved areas, reducing disparities. A unified approach ensures efficient, patient-centered care, enhancing outcomes for all.

Panelists discuss how they engage patients in shared decision-making by prioritizing open communication, discussing treatment options in the context of both clinical factors and patient preferences, and using strategies such as decision aids and detailed counseling to ensure that patient values and quality of life are fully integrated into the treatment planning process.

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.

Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative processes, and collaborative data exchange.

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.

Panelist discusses how organizations can justify the cost of Centers of Excellence for HS by improving patient outcomes, reducing complications, and enhancing care efficiency. Metrics for evaluating multidisciplinary care include patient satisfaction, quality of life, clinical improvements, and reduction in hospitalizations.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy that provides significant clinical benefits and improves overall survival compared with traditional chemotherapy.

Panelists discuss how the successful management of iron deficiency anemia requires a comprehensive approach combining early detection, appropriate choice of iron formulation, careful monitoring of treatment response, and addressing barriers to care while emphasizing the importance of patient education and health care system support in achieving optimal outcomes.

Panelists discuss how expanding patient education initiatives through digital health tools, community outreach, and health care provider collaboration could improve early recognition of IDA symptoms and treatment adherence, while emerging technologies like novel iron formulations and personalized medicine approaches may further advance treatment options in the future.

Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, professional engagement, transparent regulations, and comprehensive outcome data can help build trust in these alternative biologic treatments.